Published peptide research references
Tesamorelin
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Ahmed Samy Badran, Abdulrhman Helal, Karim Samir Shata, Hazem Ayesh · 2026
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
Aqsa Mohammed Ditta, Ruqaiya Muhammad Naeem, Muhammad Mohsin Sami, Muhammad Abdul Rafey, Hunain Ali, Muhammad Waqar Amjad, Fahad Jahangir, Kehan Ali Rizvi · 2026
EGRIFTA (tesamorelin acetate) prescribing information, revised March 2025
2025
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Ronald J Ellis, Florin Vaida, Keren Hu, Michael Dube, Brook Henry, Felicia Chow, Robert K Heaton, Daniel Lee · 2025
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Samuel C Russo, Mollie W Ockene, Allison K Arpante, Julia E Johnson, Hang Lee, Mabel Toribio, Takara L Stanley, Colleen M Hadigan · 2024
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Lindsay T Fourman, James M Billingsley, George Agyapong, Shannan J Ho Sui, Meghan N Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S Pan · 2020
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
2019
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
S Adrian, A Scherzinger, A Sanyal, J E Lake, J Falutz, M P Dubé, T Stanley, S Grinspoon · 2019
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
David R Clemmons, Sam Miller, Jean-Claude Mamputu · 2017
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Mario González-Sales, Olivier Barrière, Pierre Olivier Tremblay, Fahima Nekka, Jean-Claude Mamputu, Sylvie Boudreault, Mario Tanguay · 2015
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Mario González-Sales, Olivier Barrière, Pierre Olivier Tremblay, Fahima Nekka, Jean-Claude Mamputu, Sylvie Boudreault, Mario Tanguay · 2015
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Alexandra Mangili, Julian Falutz, Jean-Claude Mamputu, Miganush Stepanians, Brooke Hayward · 2015
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
2014
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Hideo Makimura, Caitlin A Murphy, Meghan N Feldpausch, Steven K Grinspoon · 2014
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
2012
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
Takara L Stanley, Julian Falutz, Christian Marsolais, Josée Morin, Graziella Soulban, Jean-Claude Mamputu, Hani Assaad, Ralph Turner · 2012
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
Linda M Spooner, Jacqueline L Olin · 2012
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Takara L Stanley, Julian Falutz, Jean-Claude Mamputu, Graziella Soulban, Diane Potvin, Steven K Grinspoon · 2011
Spotlight on tesamorelin in HIV-associated lipodystrophy.
Sohita Dhillon · 2011
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
Sohita Dhillon · 2011
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
2010
Tesamorelin, a human growth hormone releasing factor analogue.
Ying Wang, Brian Tomlinson · 2009
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown · 2008
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
2007
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
Brian Tomlinson · 2006